1. Volume 62, Issue 6, Pages 2230-2237 (December 2002)
Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease 
Tetsuo Shoji, Mariko Fukumoto, Eiji Kimoto, Kayo Shinohara, Masanori Emoto, Hideki Tahara, Hidenori Koyama, Eiji Ishimura, Tatsuya Nakatani, Takami Miki, Yoshihiro Tsujimoto, Tsutomu Tabata, Yoshiki Nishizawa 
Kidney International 
Volume 62, Issue 6, Pages (December 2002)
DOI: /j x
Copyright © 2002 International Society of Nephrology Terms and Conditions

2. Figure 1
Serum anti-oxidized low-density lipoprotein (anti-oxLDL) antibody titer in the cohort of patients with end-stage renal disease (ESRD). Serum anti-oxLDL antibody at baseline showed a skewed distribution with a median of 320 mU/mL (range 103 to 1558 mU/mL; N = 249).
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions

3. Figure 2
Anti-oxLDL antibody at baseline and mortality. The cohort of 249 patients with ESRD was divided into two groups according to serum titer of anti-oxLDL antibody titer, and mortality rates were compared by the Kaplan-Meier method followed by log-rank test. Those with a higher titer showed a significantly lower risk of cardiovascular mortality.
Kidney International  , DOI: ( /j x)
Copyright © 2002 International Society of Nephrology Terms and Conditions